Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status

Japanese Journal of Clinical Oncology

Volumn 44, Issue 1, 2014, Pages 42-48

  Shikina, Atsushi ^a   Shinto, Eiji ^a   Hashiguchi, Yojiro ^b   Ueno, Hideki ^a   Naito, Yoshihisa ^a   Okamoto, Koichi ^a   Kubo, Toru ^a   Fukazawa, Satomi ^a   Yamamoto, Junji ^a   Hase, Kazuo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Chemo GI tract; GI Colorectum Basic; GI Colorectum Med

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; FOLINIC ACID;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT;

EID: 84892450104     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt168     Document Type: Article

References (29)

1. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
2. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
3. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
4. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638-48.
5. Horst D, Kriegle L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-9.
6. O'brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007;445:106-10.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
8. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for anti-body-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-9.
9. Li CY, Li BX, Liang Y, et al. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56.
10. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23:450-7.
11. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. 7th edn. Chichester:Wiley-Blackwell, 2010.
12. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 major cancers in 1990. Int J Cancer 1999;83:18-29.
13. QUASR. Comparison of fluorouracil with additional levamizole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomized trial. QUASAR Collaborative Group. Lancet 2000;355:1588-96.
14. Porschen R, Bermann A, Loffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001;19:1787-94.
15. International Multicentre Pooled Analysis of Colon Cancer trials (INPACT) Investigators: efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
16. National Institute of Health Consensus Conference: adjuvant therapy for patients with colon and rectal cancer. JAMA 2006;295:2483-91.
17. Andre T, Boni C, Mounedji-Moudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
18. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
19. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16.
20. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27.
21. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26.
22. Tournigand C, de Gramont A, Louvet C, et al. A simplified bimonthly regimen with leucovorin and 5-fluorouracil for metastatic colorectal cancer. Proc Am Soc Clin Oncol 1998;17:274.
23. Shinto E, Hashiguchi Y, Ueno H, et al. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum 2011;54:1098-106.
24. Kojima M, Ishii G, Atsumi N, et al. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99:1578-83.
25. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-64.
26. Lembersky BC,Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64.
27. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23:8671-8.
28. Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-8.
29. Arkenau HT, Reiig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005;20:258-61.